Stryker Lowers Full-Year Sales and Earnings Guidance

Healthcare operators should anticipate potential equipment supply or pricing shifts after the company's third-quarter miss.

Updated on Oct. 29, 2026 in Healthcare

Isometric editorial illustration of a surgical drill bit component, representing medical technology sector challenges. — Stryker lowered its full-year earnings and sales guidance following a third-quarter miss, signaling potential headwinds for medical technology procurement and supply chains. AI Illustration. Upload story photo >

Live Poll

Does a major company missing its profit targets change how you view your personal investment strategy?

Stryker has lowered its full-year sales and earnings guidance after third-quarter results missed internal expectations. Medical device distributors and healthcare procurement teams should note the updated financial outlook as the company enters the final quarter.

Why it matters

The lowered guidance signals potential headwinds in the medical technology sector that may impact supply chain reliability and pricing for operators. Investors reacted quickly to the revision, pushing shares down 7.6 percent in after-hours trading.

Stryker reported a third-quarter profit of $753 million compared to $859 million in the same period last year, while quarterly revenue grew 7.7 percent to $6.52 billion. The company adjusted its full-year sales growth guidance to 6.5 percent to 7 percent.

The players

Stryker

A global medical technology company that develops, manufactures, and markets implants, surgical equipment, and neurotechnology devices.

The details

The firm reported uneven growth across its core segments, with MedSurg and Neurotechnology revenue rising 9.2 percent while Orthopaedics increased 5.7 percent. The earnings miss prompted management to revise full-year adjusted EPS guidance to a range of $14.80 to $14.90. These adjustments follow a year that included a cyberattack, adding complexity to the company's operational trajectory.

Earlier this year: Stryker suffered a cyberattack.
Q3 2026: Company reported lower than expected earnings.
Q4 2026: Company expects solid performance.
2027: Company expects positive momentum.

Market Landscape

This performance revision follows the 2026 corporate cyberattack incident, marking a departure from the company's recent growth stability. The updated guidance highlights broader volatility currently facing major medical device manufacturers.

Operators reliant on Stryker for surgical or neurotechnology equipment should prepare for potential adjustments in lead times or procurement pricing. Monitor the company's Q4 performance for signs of the projected stabilization heading into 2027.

The takeaway

Management has signaled a transition toward recovery following a year marked by cybersecurity disruptions and earnings volatility. Facilities managers should track the firm's adjusted earnings guidance as a proxy for broader equipment supply stability in the coming quarters.